HeartSciences Inc. (NASDAQ:HSCS) Short Interest Down 28.5% in February

HeartSciences Inc. (NASDAQ:HSCS) saw a significant decrease in short interest in February. As of February 13th, there was short interest totaling 29,772 shares, a decrease of 28.5% from the January 29th total of 41,615 shares. Approximately 1.0% of the shares of the stock are short sold. Based on an average daily volume of 20,331 shares, the days-to-cover ratio is currently 1.5 days. Based on an average daily volume of 20,331 shares, the days-to-cover ratio is currently 1.5 days. Approximately 1.0% of the shares of the stock are short sold.

Institutional Investors Weigh In On HeartSciences

A number of hedge funds have recently modified their holdings of HSCS. Geode Capital Management LLC purchased a new position in shares of HeartSciences in the second quarter worth about $43,000. TFB Advisors LLC acquired a new stake in HeartSciences in the 3rd quarter valued at about $105,000. Finally, DRW Securities LLC lifted its stake in HeartSciences by 13.7% in the 4th quarter. DRW Securities LLC now owns 95,065 shares of the company’s stock worth $294,000 after purchasing an additional 11,455 shares in the last quarter. 17.24% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

HSCS has been the subject of a number of recent analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of HeartSciences in a research report on Monday, December 29th. Ascendiant Capital Markets boosted their price target on shares of HeartSciences from $9.00 to $9.20 and gave the stock a “buy” rating in a report on Monday, December 22nd. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, HeartSciences presently has an average rating of “Hold” and an average price target of $9.20.

HeartSciences Trading Down 2.8%

NASDAQ:HSCS opened at $2.79 on Friday. The stock has a 50 day moving average of $3.07 and a two-hundred day moving average of $3.13. HeartSciences has a 12 month low of $2.01 and a 12 month high of $6.47. The firm has a market cap of $8.87 million, a P/E ratio of -0.41 and a beta of 2.52.

HeartSciences (NASDAQ:HSCS) last issued its quarterly earnings results on Monday, December 15th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.05. The firm had revenue of $2.42 million during the quarter, compared to analyst estimates of $0.00 million. On average, research analysts forecast that HeartSciences will post -10.01 earnings per share for the current year.

HeartSciences Company Profile

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.